-
Company Insights
NewSamsung Pay – Competitor Profile
Samsung Pay is a mobile payment solution launched by Samsung in August 2015. Samsung Pay is available for a range of Samsung products, including its Galaxy devices and Gear wearable technology. It was the first mobile payment offering to support NFC, magnetic secure transmission, and barcode scanning in a single solution. It is supported by more than 2,800 international and regional banks and credit unions in the US, including Bank of America, Wells Fargo, Citibank, Capital One, PNC, and TD...
-
Consumer Insights
NewMass Affluent Banking in Anglo Region – Regional Breakdown by Market Trends, Investment Preferences and Competitor Benchmarking
Mass Affluent Banking in Anglo Region Report Overview Being financially independent and asset accumulation are the primary goals for mass affluence in Anglo markets. Banks targeting the mass affluent should therefore focus on building savings and investment offerings to expand their customer bases. The ‘Mass Affluent Banking in Anglo Region’ report analyzes the behaviors and preferences of mass affluent customers in the Anglo market. This includes financial goals, banking patterns, investment preferences, and insurance preferences. The report also identifies the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pramipexole in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pramipexole in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pramipexole in Parkinson's Disease Drug Details: Pramipexole is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ampreloxetine Hydrochloride in Orthostatic Hypotension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ampreloxetine Hydrochloride in Orthostatic Hypotension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ampreloxetine Hydrochloride in Orthostatic Hypotension Drug Details: Ampreloxetine HCL (TD-9855) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ieramilimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ieramilimab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ieramilimab in Solid Tumor Drug Details: Ieramilimab (LAG-525) is under development...
-
Company Insights
Innovation and Patenting activity of TD SYNNEX Corp Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of TD SYNNEX Corp Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TD-5202 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TD-5202 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TD-5202 in Ulcerative Colitis Drug Details:TD-5202 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TD-5202 in Crohn’s Disease (Regional Enteritis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TD-5202 in Crohn's Disease (Regional Enteritis) Drug Details: TD-5202 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Umitrelimorgene Autodencel in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Umitrelimorgene Autodencel in Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Umitrelimorgene Autodencel in Glioblastoma Multiforme (GBM) Drug Details: Umitrelimorgene...